Last reviewed · How we verify
Rhu-pGSN
At a glance
| Generic name | Rhu-pGSN |
|---|---|
| Also known as | recombinant human gelsolin |
| Sponsor | BioAegis Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS) (PHASE2)
- Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers (PHASE2)
- A Study to Evaluate Plasma Gelsolin in Healthy Volunteers (PHASE1)
- Rhu-pGSN for Severe Covid-19 Pneumonia (PHASE2)
- A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP (PHASE1, PHASE2)
- Ascending Single Dose Study of Rhu-pGelsolin in Patients With Decreased Gelsolin Levels (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |